Thromboprophylaxis in pregnancy and the puerperium |
















































|
PREGNANCY
THROMBOPROPHYLAXIS
|
|
Inherited thrombophilia without
previous VTE |
Thromb
Haemost. 2001 Sep;86(3):800-3.
Risk of pregnancy-related venous thrombosis in carriers of severe inherited
thrombophilia.
Martinelli I, Legnani C, Bucciarelli P, Grandone E, De Stefano V, Mannucci
PM.
Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, IRCCS Maggiore
Hospital, University of Milan, Italy. martin@polic.cilea. It
Homozygous carriers of factor V Leiden have an approximately 80-fold
increased risk of venous thrombosis. Also double heterozygous carriers of
both the factor V Leiden and the prothrombin gene mutations are at high
thrombotic risk. The magnitude of the risk of venous thrombosis in pregnant
women with the two severe thrombophilic conditions has not been estimated so
far. We performed a multicenter retrospective family study in women with
homozygous factor V Leiden, double heterozygous factor V Leiden and the
prothrombin gene mutation, and women with normal coagulation. Only relatives
of index patients with thrombosis formed the study cohort. Fifteen
homozygous and 39 double heterozygous women were compared to 182 women with
normal coagulation. Venous thrombosis occurred in 3 of 19, 2 of 50 and 1 of
221 pregnancies, respectively. One thrombotic episode occurred in the third
trimester, the remaining 5 in the postpartum. The prevalence of venous
thrombosis was 15.8% (95% CI 3.4-39.6) for homozygotes. 4.0% (95% CI
0.5-13.7) for double heterozygotes and 0.5% for women with normal
coagulation. The relative risk of pregnancy-related venous thrombosis was
41.3 (95% CI 4.1-419.7) for homozygous and 9.2 (95% CI 0.8-103.2) for double
heterozygous carriers. In conclusion, homozygous carriers of factor V Leiden
and, to a lesser extent, double heterozygous carriers of factor V Leiden and
of the prothrombin mutation have an increased risk of venous thrombosis
during pregnancy, particularly high during the postpartum period. On the
basis of these findings we recommend that these women receive anticoagulant
prophylaxis at least in the postpartum, that should perhaps be extended to
the whole pregnancy in homozygous carriers.
Do you have an unanswered women's health question?
Please let us have your general question on our
NEW FORUM
/ MESSAGE BOARDS facility and we will try
to answer it for you. I am sure that you will appreciate that we cannot offer advice on the management of an individual's specific problem.
DISCLAIMER
The aim of this web site is to provide a general guide and it is
not intended as a substitute for a consultation with an appropriate specialist
in respect of individual care and treatment.
Thank you for your visiting us at 2womenshealth.com.
This is the personal website of David A Viniker MD FRCOG, Consultant Obstetrician and Gynaecologist at Whipps Cross University Hospital, London.
I do hope that you find the answers to your questions in the patient information and medical advice provided.
If you still have unanswered questions, please consider entering them into one of our forums and I will try to assist you.
Women's Health Home Page
|
| |
|